secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2026-05-13T11:30:40+00:00
Accession:  0001493152-26-022608
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud

MIRA Pharmaceuticals Publishes Peer-Reviewed Manuscript on SKNY-1 Preclinical Data
--------------------------------------------------------------------------------

- Manuscript titled 'SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors' published in International Journal of Molecular Sciences.
- SKNY-1 oral administration produced approximately 30% reduction in body weight from baseline after six days in the higher-dose group.
- SKNY-1 demonstrated differential CB1 signaling, partial CB2 agonist activity, and selective MAO-B inhibition relative to MAO-A.
- Preclinical findings included normalization of total cholesterol and LDL, increased HDL, reduced hepatic triglycerides, and attenuated compulsive feeding and nicotine-seeking behaviors.
- SKNY-1 has not been approved by the FDA; safety and efficacy not yet established in humans.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000149315226022608/0001493152-26-022608-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000149315226022608/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-022608

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer